Leptin is the hormone that tells the brain the body has enough fat. When it works, eating produces satiety. When it doesn't — a state called leptin resistance — the brain ignores the signal, and appetite persists regardless of energy stores. Leptin resistance accompanies most forms of obesity. For thirty years, the assumption was that chronic overnutrition permanently damages the leptin signaling pathway. The receptors degrade. The neurons stop responding. The resistance is structural.
It isn't.
Researchers found that leptin resistance in diet-induced obese mice is caused by hyperactive mTOR in hypothalamic POMC neurons. mTOR — a kinase pathway that senses nutrient availability — becomes constitutively active, blocking the downstream signaling cascade (POMC to α-MSH to MC4R) that translates leptin into satiety. The pathway isn't broken. It's stuck in the “fed” position.
Rapamycin, an mTOR inhibitor already in clinical use for transplant rejection and some cancers, reverses the resistance. Treated mice regained leptin sensitivity, reduced food intake, and lost weight — specifically fat mass, not lean tissue. The reversal worked only when the downstream melanocortin pathway was intact, confirming that mTOR hyperactivity is the bottleneck, not a symptom.
The distinction matters therapeutically. Permanent damage requires regeneration or replacement. A stuck switch requires an inhibitor. The thirty-year search for what leptin resistance destroyed was looking for the wrong kind of lesion. Nothing was destroyed. The pathway was intact, its gate jammed open by the very nutrients it was designed to sense. The sensor was blinded by its own input.
Note (2026-11-16; checked against the Rockefeller University news release for Tan and coauthors, 'A cellular and molecular basis of leptin resistance', Cell Metabolism 2025, not the paper's full text): the release confirms the study was in mice, that rapamycin reduced mTOR in POMC neurons and restored their receptivity so that the animals were resensitized to leptin, and that the weight loss was primarily a decrease in adipose tissue, with fat depots shrinking relative to muscle mass. It does not mention reduced food intake, and I did not find in it that the reversal worked only when the downstream melanocortin pathway was intact (that may be in the paper). It adds what the essay leaves out: systemic rapamycin is linked to glucose intolerance and potentially diabetes, so the researchers plan to find ways to inhibit mTOR specifically in POMC neurons. The release does not say whether the restoration is permanent or temporary, and it does not say that nothing was destroyed in leptin resistance; the essay's 'nothing was destroyed' and 'the thirty-year search was looking for the wrong kind of lesion' are its own inferences from a mouse result.